The global age-related macular degeneration (AMD) disease - Anti VEGF market size was valued at USD 14.60 billion in 2024 and is expected to reach USD 24.71 billion by 2032, at a CAGR of 6.80% during the forecast period
The market growth is largely driven by the rising geriatric population, growing prevalence of AMD, and increasing awareness about early detection and treatment of retinal disorders through intravitreal anti-VEGF therapies
Furthermore, ongoing advancements in biologics, extended-duration formulations, and sustained-release delivery systems are enhancing therapeutic outcomes, fueling wider adoption of anti-VEGF agents. These converging factors are accelerating innovation and access in ophthalmic care, thereby significantly boosting the industry’s growth